Photo: Courtesy of Teva
Teva has been handed a victory after a patent covering its multiple sclerosis drug Copaxone (glatiramer acetate) was declared valid until 2030.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Teva, Mylan, Sandoz, Copaxone, European Patent Office, Securities and Exchange Commission, patent
